🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Allergy Therapeutics (AGY)

London
Currency in GBP
Disclaimer
3.40
+0.10(+3.03%)
Closed
AGY Scorecard
Fair Value
Day's Range
3.333.80
52 wk Range
0.803.90
Bid/Ask
3.30 / 4.00
Prev. Close
3.3
Open
3.4
Day's Range
3.33-3.8
52 wk Range
0.8-3.9
Volume
1,658,438
Average Volume (3m)
843,172
1-Year Change
-47.2%
Shares Outstanding
4,766,439,938
Fair Value
Unlock
Dividends Payment Streak
Unlock
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Daily
Weekly
Monthly
More
How do you feel today about AGY?
Vote to see community's results!
or
  • UK Stocks-Factors to watch on Sept 23
    • ByReuters
  • UK Stocks-Factors to watch on Sept. 25
    • ByReuters
  • UK Stocks-Factors to watch on Sept. 26
    • ByReuters

Allergy Therapeutics Company Profile

Allergy Therapeutics plc, a commercial biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Acarovac Plus, Pollinex, Synbiotics, and VLP Peanut. The company develops allergy vaccines for pollen, house dust mites, and animal fur, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.